<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01932853</url>
  </required_header>
  <id_info>
    <org_study_id>QM-RR-02</org_study_id>
    <nct_id>NCT01932853</nct_id>
  </id_info>
  <brief_title>Association Between Dose Dialysis by Kt and Mortality</brief_title>
  <official_title>Evaluation of the Association of Dialysis Dose Obtained by Kt and Mortality in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NephroCare Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NephroCare Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether patients receiving current recommendations of an&#xD;
      adequate dialysis dose by Kt adjusted for body surface area improved survival at 24 months&#xD;
      compared to those who do not get it, as well as assess whether patients receiving a dose&#xD;
      greater obtain more benefit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality and hospitalization cause</measure>
    <time_frame>two years</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6129</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>Hemodialysis patients</arm_group_label>
    <description>Patients &gt; 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study subjects:&#xD;
&#xD;
        Patients&gt; 18 years in hemodialysis treatment at any FMC center of Spain that meet the&#xD;
        inclusion criteria.&#xD;
&#xD;
        Data will be collected according to clinical practice and patients will be categorized&#xD;
        according to their dose of Kt, along the two years of the study. Will seek the association&#xD;
        of dialysis dose with mortality and hospitalization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years old&#xD;
&#xD;
          -  &gt; six months on hemodialysis&#xD;
&#xD;
          -  Receiving 3 sessions of dialysis per week&#xD;
&#xD;
          -  Having 5 or more valid measures of Kt during the month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active chronic inflammatory diseases&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Neoplasms&#xD;
&#xD;
          -  Chronic immunosuppression or use of anti-inflammatory&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesc Maduell, MD, Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servei Nefrologia, ICNU, Hospital Cl√≠nic.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NephroCare Spain</name>
      <address>
        <city>Madrid</city>
        <zip>28042</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>August 27, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2013</study_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NephroCare Spain</investigator_affiliation>
    <investigator_full_name>Rosa Ramos</investigator_full_name>
    <investigator_title>MD, Ph</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

